Physician profile
Daniel M Nasr
NPI 1033327309
$5,825.12
in general payments reported to CMS, 2019-2025
45 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $310 · 2021: $624 · 2022: $1,034 · 2023: $752 · 2024: $1,378 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,766.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $704.48 | 2019-2025 | Octrode, Penta, Eterna |
| Nevro Corp. | $662.36 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $574.74 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $566.33 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Intracept Rf Probe |
| Vertos Medical, INC. | $493.16 | 2021-2024 | Mild Device Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.02 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $252.84 | 2020-2025 | Ztlido |
| Ibsa Pharma INC. | $234.98 | 2022-2025 | Tirosint, Licart, Tirosint |
| Medtronic USA, INC. | $193.61 | 2019 | |
| Abbvie INC. | $142.21 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.58 | 2022 | |
| Pfizer INC. | $120.26 | 2019-2024 | |
| Relievant Medsystems, INC. | $117.01 | 2022 | |
| Daiichi Sankyo INC. | $103.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $93.53 | 2019-2025 | Wainua |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nasr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.